Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J.

BMC Health Serv Res. 2013 Feb 13;13:60. doi: 10.1186/1472-6963-13-60.

PMID:
23406481
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913. doi: 10.1002/14651858.CD007913.pub2. Review.

PMID:
23076939
[PubMed - indexed for MEDLINE]
3.

Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.

Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.

Value Health. 2005 Jan-Feb;8(1):47-52.

PMID:
15841893
[PubMed - indexed for MEDLINE]
4.

Accuracy of identifying neutropenia diagnoses in outpatient claims data.

Kim SY, Solomon DH, Liu J, Chang CL, Daniel GW, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):709-13. doi: 10.1002/pds.2157. Epub 2011 May 12.

PMID:
21567653
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Colony-stimulating factors for the management of neutropenia in cancer patients.

Dale DC.

Drugs. 2002;62 Suppl 1:1-15. Review.

PMID:
12479591
[PubMed - indexed for MEDLINE]
6.

A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.

Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D.

Leuk Lymphoma. 2000 Apr;37(3-4):351-60.

PMID:
10752986
[PubMed - indexed for MEDLINE]
7.
8.

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.

Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS, Kim TW, Lee KH.

Support Care Cancer. 2011 Aug;19(8):1151-8. doi: 10.1007/s00520-010-0928-4. Epub 2010 Jun 16.

PMID:
20552376
[PubMed - indexed for MEDLINE]
9.

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.

J Clin Oncol. 2005 Nov 1;23(31):7974-84.

PMID:
16258098
[PubMed - indexed for MEDLINE]
Free Article
10.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.

Gerlier L, Lamotte M, Awada A, Bosly A, Bries G, Cocquyt V, Focan C, Henry S, Lalami Y, Machiels JP, Mebis J, Straetmans N, Verhoeven D, Somers L.

BMC Cancer. 2010 Nov 23;10:642. doi: 10.1186/1471-2407-10-642.

PMID:
21092320
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies.

Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M, Loizidou A, Barette M, Costantini S, Delmelle M, Dubreucq L, Vekemans M, Ferrant A, Bron D, Paesmans M.

Ann Oncol. 2009 Mar;20(3):513-9. doi: 10.1093/annonc/mdn655. Epub 2009 Jan 12.

PMID:
19139177
[PubMed - indexed for MEDLINE]
Free Article
12.

Health care use and primary prophylaxis with colony-stimulating factors.

Sullivan SD, Ramsey SD, Blough DK, McDermott CL, Clarke L, McCune JS.

Value Health. 2011 Mar-Apr;14(2):247-52. doi: 10.1016/j.jval.2010.09.005.

PMID:
21402293
[PubMed - indexed for MEDLINE]
13.

Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.

Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS.

Am J Hematol. 2003 Aug;73(4):263-6.

PMID:
12879430
[PubMed - indexed for MEDLINE]
14.

Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study.

Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kühne T, Popovic MB, Lüthy AR, Aebi C.

J Clin Oncol. 2010 Apr 20;28(12):2008-14. doi: 10.1200/JCO.2009.25.8988. Epub 2010 Mar 15.

PMID:
20231680
[PubMed - indexed for MEDLINE]
Free Article
15.

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

Mayordomo JI, López A, Viñolas N, Castellanos J, Pernas S, Domingo Alonso J, Frau A, Layola M, Antonio Gasquet J, Sánchez J; ENIA Study Group.

Curr Med Res Opin. 2009 Oct;25(10):2533-42. doi: 10.1185/03007990903209563.

PMID:
19722781
[PubMed - indexed for MEDLINE]
16.

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B.

J Clin Oncol. 2005 Jun 20;23(18):4198-214.

PMID:
15961767
[PubMed - indexed for MEDLINE]
Free Article
17.

Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.

Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G.

Am J Clin Oncol. 2012 Jun;35(3):267-74. doi: 10.1097/COC.0b013e31820dc075.

PMID:
21378538
[PubMed - indexed for MEDLINE]
18.

A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.

Rondinelli PI, Ribeiro Kde C, de Camargo B.

J Pediatr Hematol Oncol. 2006 Oct;28(10):665-70.

PMID:
17023827
[PubMed - indexed for MEDLINE]
19.

Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.

Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A, Deeter R, Barron R.

J Med Econ. 2013;16(1):160-8. doi: 10.3111/13696998.2012.734885. Epub 2012 Oct 11.

PMID:
23016568
[PubMed - indexed for MEDLINE]
20.

Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.

Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.

PMID:
23040435
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk